{"id":957,"date":"2021-04-29T07:09:45","date_gmt":"2021-04-29T07:09:45","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=957"},"modified":"2021-04-29T07:09:45","modified_gmt":"2021-04-29T07:09:45","slug":"06-apr-2021-hydroxychloroquine-in-this-underpowered-trial-patients-did-not-experience-better-clinical-outcomes","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/06-apr-2021-hydroxychloroquine-in-this-underpowered-trial-patients-did-not-experience-better-clinical-outcomes\/","title":{"rendered":"(06 Apr 2021) Hydroxychloroquine- in this underpowered trial patients  did not experience better clinical outcomes"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.cmi.2021.03.005<\/p>\n<p class=\"\">The trial was stopped after 250 patients were included due to a slowdown of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 (interquartile range 58 &#8211; 86) years and 151\/250 (60.4%) patients required oxygen therapy. The primary endpoint occurred in 9\/124 (7.3%) patients in the hydroxychloroquine group and 8\/123 (6.5%) patients in the placebo group (relative risk 1.12; 95% confidence interval 0.45- 2.80). The rate of positive SARS-CoV-2 RT-PCR at day 5 and 10 was 72.8% (75\/103) and 57.1% (52\/91) in the hydroxychloroquine group, versus 73.0% (73\/100) and 56.6% (47\/83) in the placebo group, respectively. No difference was observed between the two groups in any of the other secondary endpoints. In this underpowered trial involving mainly older patients with mild-to-moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial https:\/\/doi.org\/10.1016\/j.cmi.2021.03.005 The trial was stopped after 250 patients were included due to a slowdown of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/06-apr-2021-hydroxychloroquine-in-this-underpowered-trial-patients-did-not-experience-better-clinical-outcomes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(06 Apr 2021) Hydroxychloroquine- in this underpowered trial patients  did not experience better clinical outcomes&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,9],"tags":[10],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/957"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=957"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/957\/revisions"}],"predecessor-version":[{"id":958,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/957\/revisions\/958"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}